United States: CMS Proposes Several Changes To Reimbursement For Transformative Medical Technologies

Key Points

  • In recent proposed rulemaking, the Centers for Medicare and Medicaid Services (CMS) make several significant recommendations that incentivize innovation and break down patient barriers to accessing cutting-edge medical technology.
  • CMS proposes a more expansive approach to how the agency assesses "substantial clinical improvement" for purposes of determining whether a new medical technology merits a new technology add-on payment (NTAP) under the Medicare Inpatient Prospective Payment System.
  • CMS also proposes to develop an alternative pathway to receive an NTAP payment for medical technologies that are part of the Food and Drug Administration (FDA) Breakthrough Device Program.
  • Finally, CMS proposes to increase the NTAP payment calculation methodology to further incentivize innovation.

On April 23, 2019, CMS issued its FY 2020 hospital inpatient prospective payment system (IPPS) proposed rule (IPPS Proposed Rule).1 The IPPS Proposed Rule addresses many critical Medicare coding, coverage and reimbursement issues, including new medical technology that offers improved solutions for patients but that might add to the cost of a medical procedure or treatment. Under the IPPS Proposed Rule, CMS suggests several changes to how the agency grants new technology add-on payments under IPPS and similar transitional pass-through payments under the outpatient equivalent, the Outpatient Prospective Payment System (OPPS).

  • First, CMS proposes to recalibrate how it analyzes and appraises "substantial clinical improvement" for determining which medical technology merits IPPS add-on payments and OPPS transitional pass-through payments.
  • Second, CMS proposes to eliminate the substantial clinical improvement criteria for medical technology participating in the FDA Breakthrough Device Program.
  • Third, CMS seeks comments on a proposal to increase the value of the IPPS new technology add-on payment.

CMS' proposed revisions would likely result in increased payment for new and transformative medical technology and would also provide a mechanism for swift uptake in these settings. These policies reflect a shift in the agency's approach, signaling support for more and better patient access. CMS is moving in the same direction as the FDA and consistent with Congressional intent in establishing the Breakthrough Pathway in the 21st Century Cures Act, as further outlined below.

Appropriate Substantial Clinical Improvement Criteria

CMS examines several factors when determining whether new medical technology should receive an NTAP under the IPPS or a transitional pass-through payment under the OPPS. Among these factors are the technology's novelty, the technology's cost and whether the technology represents a "substantial clinical improvement" over existing technology.

"Substantial clinical improvement" is at the core of criteria used to evaluate a technology that is the subject of an application for an NTAP payment or transitional pass-through payment.2 Currently, CMS' NTAP payment application looks to the following when analyzing whether a new medical technology represents a "substantial clinical improvement:"

  • Whether the medical technology offers a treatment option for a patient population unresponsive to or ineligible for current available treatments.
  • Whether the medical technology offers the ability to diagnose a condition in a patient population (a) where that condition is currently undetectable or (b) earlier than allowed by currently available methods.
  • Whether use of the technology significantly improves clinical outcomes for a patient population as compared to currently available treatments.

CMS reviews similar criteria requested on the OPPS transitional pass-through application as well.3

In the IPPS Proposed Rule, CMS seeks comments on changes to the IPPS and OPPS substantial clinical improvement criterion. CMS has solicited feedback on the following:

  • What role should substantial clinical improvement play without discouraging appropriate utilization of new medical technologies?
  • How should CMS determine which existing technologies are appropriate comparators to new technologies?
  • More specificity on types of evidence or study designs considered by CMS in evaluating substantial clinical improvement?
  • What is the appropriate data to demonstrate whether the use of technology substantially improves clinical outcomes relative to existing technologies?
  • Should the data be focused on the Medicare population?
  • What clinical outcomes and patient reported measures should be assessed?
  • What types of study designs, criteria or methodologies could a new technology use to demonstrate substantial clinical improvement?
  • Are there certain technically or ethically challenging designs for specific medical technologies and should that be more explicitly reflected in the regulations?
  • Should potential limitations related to cross-trial comparisons with existing therapies be more explicitly reflected in the regulations?
  • Can CMS infer substantial clinical improvement under certain circumstances (e.g., technical or financial challenges to study accrual)?
  • Should CMS consider evidence regarding the off-label use of a new technology?

For add-on payment applications and transitional pass-through payment applications received beginning in FY 2020 for IPPS and CY 2020 for OPPS, respectively, CMS is considering adopting regulatory changes to the substantial clinical improvement criteria. Namely, CMS is seeking comments on whether the agency should adopt the following policy changes:

  • Adopt a policy explicitly specifying that an applicant can meet "substantial clinical improvement" if it demonstrates that new technology would be broadly adopted among applicable providers and patients.
  • Adopt a definition of the term "substantially improves" meaning that the new technology has demonstrated positive clinical outcomes that are different from existing technologies, including that improvement may always be demonstrated by comparison to existing technology.
  • Adopting a policy that the relevant information for purposes of a finding of substantial clinical improvement does not require a peer-reviewed journal article.
  • Adopting a policy that the substantial clinical improvement criterion may be met regardless of the size of the subset patient population where improvement is shown.
  • Adopting a policy specifying that "substantially improves" can be met through real-world data and evidence, but that such evidence is not required. 

    This could include decreased mortality rate; reduction in length of stay; reduced recovery time; reduced complications; decreased subsequent interventions; reduction in adverse events; decreased future hospitalizations; more rapid resolution of treatment; improvement in daily living or quality of life.
  • Adopting a policy that addresses that the substantial clinical improvement criterion can be met without regard to the FDA pathway for the technology.

Proposed Alternative Pathway for Transformative New Devices

Also in its IPPS Proposed Rule, CMS proposes a new pathway for transformative medical technology seeking an add-on payment under the IPPS. Specifically, CMS proposes that for applications received for IPPS new technology add-on payments for FY 2021 and beyond:

  • If a medical device is part of the FDA's Breakthrough Device Program (i.e., designated by FDA to be a breakthrough device) and has received FDA marketing authorization, the device would be considered new and not substantially similar to an existing technology.
  • For these transformative devices, because the technology may lack sufficient evidence to show substantial clinical improvement at the time of FDA marketing authorization, CMS proposes that the device does not need to show substantial clinical improvement to qualify for the add-on payment.

The current breakthrough pathway for devices was established in 2016 by the 21stCentury Cures Act ("Cures"), in an effort to facilitate timely access for U.S. patients for devices that would represent a "breakthrough" in diagnosis or treatment. However, Cures did not address coverage and reimbursement of these new, breakthrough devices. Congress modeled the regulatory program for breakthrough devices on the breakthrough pathway for drugs. As enacted, the program is available to qualifying devices that will go through the premarket approval (PMA), de novo, or 510(k) pathways. To qualify, a device must demonstrate that it provides for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating human disease or condition, and meets one of the following criteria:

  • It represents a breakthrough technology
  • It has no approved or cleared alternative
  • It offers significant advantages over existing approved or cleared alternatives, including "the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients' ability to manage their own care . . . , or establish long-term clinical efficiencies"
  • Its availability is in the best interest of patients.4

Breakthrough devices granted priority review are not guaranteed a faster review than nonbreakthrough devices, though they are prioritized in the agency's review queue and assigned additional review resources. As directed by Cures, the FDA issued guidance on the Breakthrough Device Program, and finalized its policies in December of 2018. Among other things, the guidance details the scope of the program, agency interactions with sponsors of a breakthrough-designated device (including "sprint meetings," intended to address specific issues and testing protocols), and clinical trial considerations for breakthrough devices.

In addition to proposing a specific pathway for FDA Breakthrough Devices, CMS has also asked for public comments on the following:

  • How should CMS compare the risks (i.e., risk of adverse events or negative outcomes) vs. the benefits (i.e., facilitate beneficiary access to transformative new medical devices; mitigate potential delayed access to innovation and adoption) of the proposed pathway?
  • CMS also asks whether the newness period under the proposed alternative payment pathway should be limited to a period of time sufficient for the evidence base to develop to the point where a substantial clinical improvement determination can be made. For example, one to two years after approval, depending on whether the transformative new medical device would be eligible for a third year of new technology add-on payments. CMS also notes that the newness period for a transformative new medical device cannot exceed three years.

Proposed Revision to Add-On Payment Calculation

Finally, CMS proposes increasing the amount of the IPPS new technology add-on payment. Currently, CMS bases new technology add-on payments on the cost to the hospital for the new medical technology. Under 42 C.F.R. § 412.88, if the costs of the discharge exceed the full diagnosis-related group (DRG) payment, Medicare makes an add-on payment equal to the lesser of: (1) 50 percent of the costs of the new medical technology or (2) 50 percent of the amount by which the costs of the case exceed the standard DRG payment.

The agency notes that feedback has indicated this calculation does not reflect the true costs of new medical technology and dissuades innovation. Accordingly, CMS has solicited comments on a proposed increase in the amount to the lesser of: (1) 65 percent of the costs of the new medical technology; or (2) 65 percent of the amount by which the costs of the case exceed the standard DRG payment.


1 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Proposed-Rule-Home-Page.html.

2 42 C.F.R. § 412.87(b); 42 C.F.R. § 419.66(b). 42 C.F.R. § 412.87(b)(1); see also 42 C.F.R. § 419.66(c).

3 See id.

4 For a more in-depth discussion of the Breakthrough Device Program, as enacted by Cures, see Akin Gump's Health Industry Alert, "Key Implications of the 21st Century Cures Act for Medical Devices," https://www.akingump.com/en/news-insights/key-implications-of-the-21st-century-cures-act-for-medical.html.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions